Venture Report: Big rounds for Candid, Superluminal, PanTera

VCs played key roles in the $370 million launch of Candid via the combination of two other venture-backed companies this week, while Superluminal and PanTera each drew large series A rounds.

Four firms co-led a new round for San Diego-based Candid Therapeutics Inc., a start-up that will unite two existing companies under one roof to advance repurposed, in-licensed therapies for immunological disorders. Candid has acquired Vignette Bio Inc., a company created by Foresite Capital, and TRC 2004 Inc., backed by Third Rock Ventures and Two River; each held ex-China rights to bispecific compounds that had previously been tested in oncology...